Professional Posters – Descriptive Research Reports

Descriptive Research Reports describe new, improved or innovative roles or services in managed care pharmacy practice that are of such importance that they should be brought to the attention of other pharmacy professionals. The following posters were selected for presentation:

**PRR-01**: Real-World Data on Patient Adherence to the Rivastigmine Transdermal System after Switching from an Oral Cholinesterase Inhibitor, Safiya Abouzaid, PharmD, Assistant Director, Neuroscience and Psychiatry, Health Economics and Outcomes Research, Novartis Pharmaceuticals

**PRR-02**: Resource Utilization and Costs Associated with Insomnia Treatment in Patients with Major Depressive Disorder, Safiya Abouzaid, PharmD, Assistant Director, Neuroscience and Psychiatry, Health Economics and Outcomes Research, Novartis Pharmaceuticals

**PRR-03**: Plan Savings from Stepped Generic Copay Reduction, Abigail Brinkman, Analytic Consultant, CVS Caremark

**PRR-04**: Costs, Absences, Prevalence and Impact of Bipolar Disorder, Other Mental Disorders, Chronic Constipation, Functional Dyspepsia, GERD, Gout, and Insomnia, Richard Brook, MS, MBA, Head, Retrospective Analysis, The JeSTARx Group

**PRR-05**: Patient-Reported Psoriasis Disease Flaring and Impact of Flare Frequency on Humanistic Outcomes, Chureen Carter, PharmD, MS, Associate Director, Health Economics and Outcomes Research, Janssen Biotech, Inc.

**PRR-06**: Psoriasis and Psoriatic Arthritis Patient Productivity Burden in the United States, Chureen Carter, PharmD, MS, Associate Director, Health Economics and Outcomes Research, Janssen Biotech, Inc.

**PRR-07**: Prevalence of Upper Gastrointestinal Symptoms in the United States: A Systematic Literature Review, Craig Coleman, PharmD, Associate Professor, University of Connecticut School of Pharmacy

**PRR-08**: Lower Medication Utilization is Associated with Higher Healthcare Costs in Parkinson’s Disease Patients, Tracy Durgin, PharmD, Senior Medical Science Liaison - CNS, UCB Pharma Inc.

**PRR-09**: Patient Perceptions and Experiences with Sites of Care Among Patients with Immunology Conditions Currently Using Intravenous Biologic Therapy, Lorie Ellis, PhD, Associate Director, Translational Sciences, Health Economics and Outcomes Research, Janssen Biotech, Inc.

**PRR-10**: Longitudinal Analysis of Golimumab Utilization: Evidence from The Wolters Kluwer Source LX National Health Claims Database, Lorie Ellis, PhD, Associate Director, Translational Sciences, Health Economics and Outcomes Research, Janssen Biotech, Inc.

**PRR-11**: Palivizumab (Synagis) Treatment Course Fulfillment Via a Specialty Pharmacy Compared to Non-Specialty, Patrick Gleason, PharmD, BCPS, FCCP, Director, Clinical Outcomes Assessment, Prime Therapeutics LLC

**PRR-12**: Cost Effectiveness of Warfarin Compared to Dabigatran, Patrick Gleason, PharmD, FCCP, BCPS, Director, Clinical Outcomes Assessment, Prime Therapeutics LLC
**PRR-13**: Multidisciplinary Approach to Management of Atypical Antipsychotics in an Adolescent Population, John Hogge, PharmD, Senior Director, Clinical Services, HealthTrans

**PRR-14**: Impact of Side Effects of Hydrocodone or Oxycodone Immediate-Release: Patient-Reported Bother and Other Medication Use, Andrew Howe, PharmD, BA, Associate Director, Translation Science, Health Economics and Outcomes Research, Janssen Scientific Affairs, LLC

**PRR-15**: Characteristics of Patients Taking Oxycodone Controlled-Release and Related Medical Resource Use, Andrew Howe, PharmD, BA, Associate Director, Translation Science, Health Economics and Outcomes Research, Janssen Scientific Affairs, LLC

**PRR-16**: Titration with Gabapentin and Pregabalin Therapy in Patients with Post-Herpetic Neuralgia (PHN), Phaedra Johnson, MS, Researcher, OptumInsight

**PRR-17**: Evaluating the Impact of Varenicline Adherence on Quit Rates in the Geisinger Clinic, Joshua Liberman, PhD, Vice President, Research Operations, Geisinger Center for Health Research

**PRR-18**: Impact of a Reference Based Pricing Program for Select Drug Classes, Jack Lin, MS, MBA, Senior Analytic Consultant, Analytics and Outcomes, CVS Caremark

**PRR-19**: Healthcare Costs Associated with Switching of Biologic Disease Modifying Anti-Rheumatic Drugs, Brian Meissner, PharmD, PhD, Director, Bristol-Myers Squibb

**PRR-20**: Medicaid Pharmacy Benefit Carve-Outs and Their Impact on Generic Dispensing Rates and Implied Program Costs, Stuart Miller, MS, MBA, Manager, Analytic Consulting, CVS Caremark

**PRR-21**: Persistence with Growth Hormone Therapy by Pediatric Patients: Results from the ANSWER Program, Bradley Miller, MD, PhD, Assistant Professor of Pediatrics, University of Minnesota Amplatz Children’s Hospital

**PRR-22**: Evaluation of an Interactive Voice Response (IVR) Statin Adherence Program, Matthew Mitchell, PharmD, MBA, Manager, Pharmacy Services, SelectHealth

**PRR-23**: Assessment of Healthcare Resource Utilization by Level of Flare Severity in Patients with Systemic Lupus Erythematosus (SLE) in the Managed Care Setting, Alan Oglesby, MPH, Director, U.S. Health Outcomes Research, GlaxoSmithKline

**PRR-24**: Health Care Costs Among Gout Patients on Allopurinol and Febuxostat, Gabriel Gomez Rey, Lead Analyst, Health Economics and Outcomes Research, OptumInsight

**PRR-25**: Clinical Inertia Associated with Rejected Aliskiren Claims, Bimal Patel, PharmD, MS, Director, Health Outcomes Research, MedImpact Healthcare Systems, Inc.
**PRR-39:** Association Between Osteoporosis Treatment Change and Total Direct Healthcare Costs in Medicare Advantage Prescription Drug (MAPD) Plan, Melea Ward, PharmD, MS, Clinical Research Consultant, Competitive Health Analytics, Inc.

**PRR-40:** The Effects of a High Cost Generic Program on Drug Expenditures, Feng Zeng, PhD, Health Economist, MedImpact Healthcare Systems, Inc.